BIT 5.00% 1.9¢ biotron limited

Take Over Offer is over the cup for sure!, page-3

  1. 2,684 Posts.
    lightbulb Created with Sketch. 739
    Might be helpful for readers to recall what you said back on 30 March 2022 to help them decide how much credibility your posts have.

    You wrote (see here):

    "BIT, being a back-bench biotech, has shown it has remarkable compunds and evidence-driven outcome that it was able to send to FDA's court.
    The CEO is showing progress!
    BIT, this year, can demonstrate many potential breakthrough - potential outcome from the ongoing works in many fronts, securing commercial partnership deals, SP reaching all-time high around $1 per share, ... My gut feeling. DYOR!"

 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.